Back to top
more

Silk Road Medical (SILK)

(Delayed Data from NSDQ)

$17.32 USD

17.32
373,078

-0.10 (-0.57%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $17.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio

Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.

Silk Road Medical (SILK) Upgraded to Buy: What Does It Mean for the Stock?

Silk Road Medical (SILK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio

Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.

Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of 17.50% and 11.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Stock Jumps 12.7%: Will It Continue to Soar?

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shockwave Medical (SWAV) Q3 Earnings and Revenues Beat Estimates

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 13.58% and 0.64%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for

Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of 10.26% and 4.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in RxSight, Inc. (RXST): Can Its 9.6% Jump Turn into More Strength?

RxSight, Inc. (RXST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Silk Road Medical (SILK) Reports Q1 Loss, Lags Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of -10.26% and 1.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.11% and 15.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of 21.95% and 12.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Q3 Earnings and Revenues Beat Estimates

Accuray (ARAY) delivered earnings and revenue surprises of 200% and 6.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of 8.11% and 7.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of 23.81% and 0.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 3.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

What Makes Silk Road Medical (SILK) a New Strong Buy Stock

Silk Road Medical (SILK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Indrajit Bandyopadhyay headshot

5 Winning Medical Product Stocks That Still Have Room to Run

Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.

Silk Road Medical (SILK) is a Great Momentum Stock: Should You Buy?

Does Silk Road Medical (SILK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Silk Road Medical (SILK) Reports Q3 Loss, Tops Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of 34.09% and 10.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Stock Jumps 6.7%: Will It Continue to Soar?

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Silk Road Medical (SILK): Can Its 9.3% Jump Turn into More Strength?

Silk Road Medical (SILK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of 6.38% and 6.91%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q1 Loss, Tops Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of -17.07% and 5.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of -5% and 8.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?